Charles Rudin
 | Academic Degrees Departmental Affiliation Departmental Address |
Research and Professional Experience
Dr. Rudin is the Principal Investigator of the FAMRI Center of Excellence in Translational Research at Johns Hopkins. Dr. Rudin was recruited from the University of Chicago in 2004 to provide leadership in translational and therapeutic application in the Upper Aerodigestive Cancer Program. He is currently an Associate Professor of Oncology, a member of the graduate training programs in Clinical and Molecular Medicine and Pharmacology, and has leadership roles in both the Upper Aerodigestive Cancer Program and the Specimen Accessioning Core of the Cancer Center. Dr. Rudin directs a broad program of integrated basic, translational and clinical research. His laboratory is focused primarily on how defects in cell death pathways contribute to cancer development and chemotherapeutic resistance, and on how modulation of these pathways can be exploited to improve cancer therapy. Among other projects, Dr. Rudin�s group is exploring the integration of metabolic and survival signaling pathways in cancer cells, and conducting preclinical analysis of small molecule inhibitors of Bcl-2 in small cell lung cancer models. Recent clinical research projects in early phase drug development include evaluation of a replication-competent adenovirus as a mouthwash to prevent oral cancer, and evaluation of antisense inhibition of Bcl-2 as a novel chemosensitizing agent for patients with small cell lung cancer. The latter work has been recently recognized with the Annals of Oncology Prize for the best article on early clinical research published in the previous 2 years. He is a member of the Eastern Cooperative Oncology Group (ECOG) Thoracic Core Committee, and of the Lung Cancer Biology Subcommittee. He serves on advisory boards for several companies focused on novel therapeutic approaches to malignancy and is on the editorial boards of the Journal of Clinical Oncology and Investigational New Drugs. Dr. Rudin reviews grant proposals for several private foundations and has been appointed a permanent member of the NIH Clinical Oncology (CONC) Study Section.
